Snibe Diagnostic

Oncolytic Virus – Synergism from Combined Immunologic Inhibition

Intravenous administration and combination therapy are the development direction of the oncolytic virus.

Insgeek Nets Hundreds of Mns of CNY in Series D Round

Digitalization of group insurance helps improve efficiency.

Chimigen Bio Nets Over 100 Mn CNY in First Financing Round

The proceeds will be used for the advancement of its first two product pipelines.

Blood Cancer, ‘Bloody Invisible Invader’ in China

Blood cancers including leukemia, lymphoma and myeloma are the top 10 cancer diseases worldwide. However, due to their distinct features from solid cancers, the diagnosis of them is much more challenging and requires extra care. Patients possessing blood cancers often have less awareness and blood cancers can be a so-called the invisible invader. This article gives an introduction to blood cancers then generally dissects what challenges the industry is facing in China.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.